Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Inventiva ( (IVA) ) has issued an update.
On July 7, 2025, Inventiva announced the receipt of a $10 million milestone payment from Chia Tai-Tianqing Pharmaceutical Group Co., Ltd (CTTQ) as part of their licensing and collaboration agreement to develop and commercialize lanifibranor for MASH in China and other regions. This payment follows the successful settlement of a significant tranche in their structured financing, highlighting the company’s progress in its partnership with CTTQ and its strategic focus on expanding its market presence in Asia. The collaboration with CTTQ, which includes participation in the NATiV3 pivotal Phase 3 clinical trial, positions Inventiva to potentially accelerate regulatory approval processes in China, enhancing its competitive stance in the biopharmaceutical industry.
The most recent analyst rating on (IVA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
Inventiva’s overall stock score is primarily impacted by its poor financial performance and challenging valuation. While the earnings call provides some optimism with clinical progress and strategic initiatives, these do not offset the substantial financial difficulties and negative valuation metrics. The technical analysis offers a neutral outlook, with no strong indicators for immediate price movement.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company that focuses on the research and development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in a pivotal Phase 3 clinical trial for treating adult patients with MASH, a progressive chronic liver disease. Inventiva is publicly listed on Euronext Paris and the Nasdaq Global Market.
Average Trading Volume: 20,517
Technical Sentiment Signal: Sell
Current Market Cap: $429.5M
See more insights into IVA stock on TipRanks’ Stock Analysis page.